{
    "Trade/Device Name(s)": [
        "QMS\u00ae Amikacin"
    ],
    "Submitter Information": "Seradyn, Inc",
    "510(k) Number": "K052815",
    "Predicate Device Reference 510(k) Number(s)": [
        "K802669"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "KLQ"
    ],
    "Summary Letter Date": "November 1, 2005",
    "Summary Letter Received Date": "October 4, 2005",
    "Submission Date": "October 3, 2005",
    "Regulation Number(s)": [
        "21 CFR 862.3035"
    ],
    "Regulation Name(s)": [
        "Amikacin test system"
    ],
    "Analyte Class(es)": [
        "tdm",
        "toxicology"
    ],
    "Analyte(s)": [
        "Amikacin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous particle-enhanced turbidimetric immunoassay (particle agglutination)"
    ],
    "Methodologies": [
        "Immunoassay",
        "Particle agglutination",
        "Turbidimetric assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for QMS\u00ae Amikacin homogeneous particle-enhanced turbidimetric immunoassay for measuring amikacin in human serum or plasma",
    "Indications for Use Summary": "Quantitative determination of amikacin in human serum or plasma on automated clinical chemistry analyzers for diagnosis and treatment of amikacin overdose and monitoring amikacin therapy",
    "fda_folder": "Toxicology"
}